Alzheimer Drug Trial Results Change 'Landscape'

September 28, 2022

"The report of this successful Phase III trial (by Eisai Co Ltd and Biogen Inc) in early Alzheimer's disease will change the landscape of Alzheimer's treatment in this country and worldwide,” said Dr. Lawrence Honig, professor of neurology at Columbia University Irving Medical Center. [watch video]

Source: Reuters